Topic
glp-1
Manufacturing Ozempic-maker Novo Nordisk sues Eli Lilly for false advertising over weight-loss drug claims
Novo Nordisk has sued Eli Lilly, alleging false advertising in Eli Lilly's campaigns that compare weight-loss and diabetes drugs. Novo claims Eli Lilly intentionally used outdated studies and omitted higher-dose options to create a misleading impression of superiority. The lawsuit seeks to pull the ads and run corrective advertising.
Manufacturing Just About Anyone Can Sell GLP-1s Online Now: Turnkey Telehealth Sparks Market Flood
The rise of turnkey telehealth services is enabling companies with no medical background—from search platforms like JustAnswer to dating apps like Grindr—to sell GLP-1 drugs online. Infrastructure firms handle software, clinician networks, and compliance, allowing new entrants to launch in as little as three hours. The trend is accelerating rapidly, with one provider reporting a minimum of one new brand launch per day.
E-Commerce & Marketplaces GLP-1 Online Scams Entangle Unsuspecting Patients, Triggering Supply Chain and R
A WIRED investigation into online telehealth provider FitRx/Zealthy reveals a pattern of deceptive billing and shipment of unwanted GLP-1 drugs like tirzepatide. Customers face denied refunds due to 'supply chain and privacy' policies, despite FDA and FTC oversight. The case highlights risks in the booming online weight-loss drug market projected to reach $150 billion.